AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

The licensing deal comes as AbbVie is weathering the impact of biosimilar competition to Humira (adalimumab), its big-selling immunology and inflammation brand used to treat a host of diseases ...

AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...

"AbbVie and Neomorph link on oncology/immunology glue degraders" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...